Abstract
Coronavirus disease 2019 (COVID-19) has caused thousands of deaths since it was declared as a pandemic and continues to be one of the most followed topics in the world in terms of its course and treatment. Favipiravir is a broad-spectrum anti-viral agent that has been shown to be effective against various Coronaviruses in vitro. However, as with any drug use, side effects may develop with the use of favipravir treatment. We aimed to present a case of angioedema and acute urticaria whom had COVID 19 pneumonia, that we cannot distinguish as a rare side effect due to favipiravir treatment or COVID-19 cutaneous manifestation. According to the available literature, this is the first case reported in our country.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
